TScan Therapeutics cut to Hold from Buy by Needham
Needham downgraded TScan Therapeutics to Hold from Buy, per Benzinga ratings actions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.